In the past week, REPL stock has gone up by 23.12%, with a monthly gain of 13.04% and a quarterly surge of 32.73%. The volatility ratio for the week is 12.13%, and the volatility levels for the last 30 days are 7.17% for Replimune Group Inc The simple moving average for the last 20 days is 10.40% for REPL stock, with a simple moving average of 44.54% for the last 200 days.
Is It Worth Investing in Replimune Group Inc (NASDAQ: REPL) Right Now?
Moreover, the 36-month beta value for REPL is 1.27. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for REPL is 54.44M and currently, short sellers hold a 12.95% of that float. On November 26, 2024, REPL’s average trading volume was 746.30K shares.
REPL) stock’s latest price update
Replimune Group Inc (NASDAQ: REPL) has seen a decline in its stock price by -11.19 in relation to its previous close of 14.93. However, the company has experienced a 23.12% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-25 that WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriter a 30-day option to purchase up to an additional $18.75 million of securities from Replimune at the public offering price, less the underwriting discounts and commissions.
Analysts’ Opinion of REPL
Many brokerage firms have already submitted their reports for REPL stocks, with ROTH MKM repeating the rating for REPL by listing it as a “Buy.” The predicted price for REPL in the upcoming period, according to ROTH MKM is $17 based on the research report published on August 28, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see REPL reach a price target of $44. The rating they have provided for REPL stocks is “Overweight” according to the report published on April 17th, 2023.
Piper Sandler gave a rating of “Overweight” to REPL, setting the target price at $52 in the report published on November 19th of the previous year.
REPL Trading at 13.88% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.00% of loss for the given period.
Volatility was left at 7.17%, however, over the last 30 days, the volatility rate increased by 12.13%, as shares surge +10.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.77% upper at present.
During the last 5 trading sessions, REPL rose by +23.12%, which changed the moving average for the period of 200-days by +70.88% in comparison to the 20-day moving average, which settled at $12.01. In addition, Replimune Group Inc saw 57.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Xynos Konstantinos, who sale 7,246 shares at the price of $10.78 back on Nov 18 ’24. After this action, Xynos Konstantinos now owns 109,885 shares of Replimune Group Inc, valued at $78,112 using the latest closing price.
Sarchi Christopher, the Chief Commercial Officer of Replimune Group Inc, sale 5,207 shares at $10.78 during a trade that took place back on Nov 18 ’24, which means that Sarchi Christopher is holding 87,045 shares at $56,131 based on the most recent closing price.
Stock Fundamentals for REPL
Current profitability levels for the company are sitting at:
- -57.29 for the present operating margin
- 0.48 for the gross margin
The net margin for Replimune Group Inc stands at -52.7. The total capital return value is set at -0.51. Equity return is now at value -50.32, with -40.17 for asset returns.
Based on Replimune Group Inc (REPL), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -3.97. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -31.16.
Currently, EBITDA for the company is -230.2 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 215.2. The receivables turnover for the company is 4.86for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.11.
Conclusion
To wrap up, the performance of Replimune Group Inc (REPL) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
